TORONTO, Feb. 06, 2025 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that it has signed an advisory agreement with Mr. Matthew Azrieli. Mr. Azrieli is a current shareholder of PharmAla Biotech.
“Having come to know Matthew well over the past number of months, I believe he will be able to significantly help PharmAla in a number of our developing markets,” said Nick Kadysh, CEO, PharmAla Biotech. “Mr. Azrieli is not only well placed to assist PharmAla in highlighting our growing Clinical Trials business in the United States, but is also well placed to assist our work in a number of other growth markets.”
The advisory agreement with Mr. Azrieli includes up to 1 million Performance Share Units, which may be released to Mr. Azrieli upon execution of pre-set corporate goals spanning 3 major categories: media advisory, market development, and investment advisory.
Investor Webinar
PharmAla will host a Webinar on February 6, 2025, at 4:30 PM Eastern Time (ET). Nicholas Kadysh, CEO, and Will Avery, CFO, will discuss the Company’s financial results, as well as the Company’s plans for the coming year.
What: PharmAla Earnings/Financials Webinar
When: February 6, 4:30PM ET
Sign-up Link: https://us06web.zoom.us/webinar/register/WN_YVwEWTKGTPKWQolPPelDtg
PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA. PharmAla was founded with a dual focus: alleviating the global backlog of generic, clinical-grade MDMA to enable clinical trials as well as commercial sales in selected jurisdictions, and to develop novel drugs in the same class. PharmAla is the only company currently provisioning clinical-grade MDMA for patient treatments outside of clinical trials. PharmAla’s research and development unit has completed proof-of-concept research into several IP families, including ALA-002, its lead drug candidate. PharmAla is a “regulatory first” organization, formed under the principle that true success in the psychedelics industry will only be achieved through excellent relationships with regulators.
For more information, please contact:
Nicholas Kadysh
Chief Executive Officer
PharmAla Biotech Holdings Inc.
Email: press@PharmAla.ca
Phone: 1-855-444-6362
Website: www.PharmAla.ca
Neither the CSE nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.